Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.


Listen to the latest hemonc news from international experts

COSTEM: the role of alloHSCT in ALL

Over the past few years, the therapeutic landscape for acute lymphoblastic leukemia (ALL) has dramatically evolved, with the development of highly effective tyrosine kinase inhibitors (TKIs) and bispecific antibodies. These therapies have considerably improved outcomes for patients and many achieve durable remissions, raising the debate of whether allogeneic hematopoietic stem cell transplantation (alloHSCT) should still be offered to all patients with ALL.

In this podcast featuring Mohamad Mohty, MD, PhD, Saint-Antoine Hospital and Sorbonne University, Paris, France, and Robin FoĆ , MD, Sapienza University of Rome, Rome, Italy, discuss the relevance of alloHSCT in the current therapeutic landscape for ALL.

Date: 25th October 2021

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter